Krenar Veselaj1, Nicole Kamber1, Myriam Briner1, Christoph Friedli1, Lara Diem1, Kirsten Guse1, Andrei Miclea1, Roland Wiest2, Franca Wagner2, Hilary Grabe3, Mathias Abegg3, Michael P Horn4, Sandra Bigi1,5, Andrew Chan1, Robert Hoepner1, Anke Salmen1. 1. Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. 2. Department of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. 3. Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. 4. Department of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. 5. Department of Pediatrics, Division of Child Neurology, University Children's Hospital Bern, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Abstract
AIMS: Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) have been proposed to define "MOG encephalomyelitis" (MOG-EM), with published diagnostic and "red flag" criteria. We aimed to evaluate these criteria in a routine clinical setting. METHODS: We retrospectively analyzed patients with borderline/positive MOG-IgG and applied the diagnostic and red flag criteria to determine likelihood of MOG-EM diagnosis. Para-/clinical parameters were described and analyzed with chi-square test. RESULTS: In total, 37 patients fulfilled MOG-EM diagnostic criteria (female-to-male ratio: 1.6:1, median onset age: 28.0 years [IQR 18.5-40.5], n = 8 with pediatric onset). In 24/37, red flags were present, predominantly MOG-IgG at assay cutoff and/or MRI lesions suggestive of multiple sclerosis (MS). As proposed in the consensus criteria, these patients should rather be described as "possible" MOG-EM. Of these, we classified 13 patients as "unlikely" MOG-EM in the presence of the red flag "borderline MOG-IgG" with negative MOG-IgG retest or coincidence of ≥1 additional red flag. This group mainly consisted of patients diagnosed with MS (n = 11). Frequency of cerebrospinal fluid (CSF-)-specific oligoclonal bands (OCB) is significantly lower in definite vs possible and unlikely MOG-EM (P = .0005). CONCLUSION: Evaluation of diagnostic and red flag criteria, MOG-IgG retesting (incl. change of assay), and CSF-specific OCB are relevant in clinical routine cohorts to differentiate MOG-EM from MS.
AIMS: Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) have been proposed to define "MOG encephalomyelitis" (MOG-EM), with published diagnostic and "red flag" criteria. We aimed to evaluate these criteria in a routine clinical setting. METHODS: We retrospectively analyzed patients with borderline/positive MOG-IgG and applied the diagnostic and red flag criteria to determine likelihood of MOG-EM diagnosis. Para-/clinical parameters were described and analyzed with chi-square test. RESULTS: In total, 37 patients fulfilled MOG-EM diagnostic criteria (female-to-male ratio: 1.6:1, median onset age: 28.0 years [IQR 18.5-40.5], n = 8 with pediatric onset). In 24/37, red flags were present, predominantly MOG-IgG at assay cutoff and/or MRI lesions suggestive of multiple sclerosis (MS). As proposed in the consensus criteria, these patients should rather be described as "possible" MOG-EM. Of these, we classified 13 patients as "unlikely" MOG-EM in the presence of the red flag "borderline MOG-IgG" with negative MOG-IgG retest or coincidence of ≥1 additional red flag. This group mainly consisted of patients diagnosed with MS (n = 11). Frequency of cerebrospinal fluid (CSF-)-specific oligoclonal bands (OCB) is significantly lower in definite vs possible and unlikely MOG-EM (P = .0005). CONCLUSION: Evaluation of diagnostic and red flag criteria, MOG-IgG retesting (incl. change of assay), and CSF-specific OCB are relevant in clinical routine cohorts to differentiate MOG-EM from MS.
Authors: Liane Dahm; Christoph Ott; Johann Steiner; Beata Stepniak; Bianca Teegen; Sandra Saschenbrecker; Christian Hammer; Kathrin Borowski; Martin Begemann; Sandra Lemke; Kristin Rentzsch; Christian Probst; Henrik Martens; Jürgen Wienands; Gianfranco Spalletta; Karin Weissenborn; Winfried Stöcker; Hannelore Ehrenreich Journal: Ann Neurol Date: 2014-06-23 Impact factor: 10.422
Authors: Yael Hacohen; Yu Yi Wong; Christian Lechner; Maciej Jurynczyk; Sukhvir Wright; Bahadir Konuskan; Judith Kalser; Anne Lise Poulat; Helene Maurey; Esther Ganelin-Cohen; Evangeline Wassmer; Chery Hemingway; Rob Forsyth; Eva Maria Hennes; M Isabel Leite; Olga Ciccarelli; Banu Anlar; Rogier Hintzen; Romain Marignier; Jacqueline Palace; Matthias Baumann; Kevin Rostásy; Rinze Neuteboom; Kumaran Deiva; Ming Lim Journal: JAMA Neurol Date: 2018-04-01 Impact factor: 18.302
Authors: Kevin Rostasy; Simone Mader; Kathrin Schanda; Peter Huppke; Jutta Gärtner; Verena Kraus; Michael Karenfort; Daniel Tibussek; Astrid Blaschek; Barbara Bajer-Kornek; Steffen Leitz; Mareike Schimmel; Franziska Di Pauli; Thomas Berger; Markus Reindl Journal: Arch Neurol Date: 2012-06
Authors: Shahd H M Hamid; Dan Whittam; Mariyam Saviour; Amal Alorainy; Kerry Mutch; Samantha Linaker; Tom Solomon; Maneesh Bhojak; Mark Woodhall; Patrick Waters; Richard Appleton; Martin Duddy; Anu Jacob Journal: JAMA Neurol Date: 2018-01-01 Impact factor: 18.302
Authors: M Baumann; K Sahin; C Lechner; E M Hennes; K Schanda; S Mader; M Karenfort; C Selch; M Häusler; A Eisenkölbl; M Salandin; U Gruber-Sedlmayr; A Blaschek; V Kraus; S Leiz; J Finsterwalder; T Gotwald; G Kuchukhidze; T Berger; M Reindl; K Rostásy Journal: J Neurol Neurosurg Psychiatry Date: 2014-08-13 Impact factor: 10.154
Authors: A K Pröbstel; K Dornmair; R Bittner; P Sperl; D Jenne; S Magalhaes; A Villalobos; C Breithaupt; R Weissert; U Jacob; M Krumbholz; T Kuempfel; A Blaschek; W Stark; J Gärtner; D Pohl; K Rostasy; F Weber; I Forne; M Khademi; T Olsson; F Brilot; E Tantsis; R C Dale; H Wekerle; R Hohlfeld; B Banwell; A Bar-Or; E Meinl; T Derfuss Journal: Neurology Date: 2011-07-27 Impact factor: 9.910
Authors: Sven Jarius; Klemens Ruprecht; Ingo Kleiter; Nadja Borisow; Nasrin Asgari; Kalliopi Pitarokoili; Florence Pache; Oliver Stich; Lena-Alexandra Beume; Martin W Hümmert; Corinna Trebst; Marius Ringelstein; Orhan Aktas; Alexander Winkelmann; Mathias Buttmann; Alexander Schwarz; Hanna Zimmermann; Alexander U Brandt; Diego Franciotta; Marco Capobianco; Joseph Kuchling; Jürgen Haas; Mirjam Korporal-Kuhnke; Soeren Thue Lillevang; Kai Fechner; Kathrin Schanda; Friedemann Paul; Brigitte Wildemann; Markus Reindl Journal: J Neuroinflammation Date: 2016-09-26 Impact factor: 8.322
Authors: Patrick J Waters; Lars Komorowski; Mark Woodhall; Sabine Lederer; Masoud Majed; Jim Fryer; John Mills; Eoin P Flanagan; Sarosh R Irani; Amy C Kunchok; Andrew McKeon; Sean J Pittock Journal: Neurology Date: 2019-02-06 Impact factor: 9.910
Authors: Lidia Stork; David Ellenberger; Klemens Ruprecht; Markus Reindl; Tim Beißbarth; Tim Friede; Tania Kümpfel; Lisa A Gerdes; Mareike Gloth; Thomas Liman; Friedemann Paul; Wolfgang Brück; Imke Metz Journal: Acta Neuropathol Date: 2020-01-16 Impact factor: 17.088
Authors: Krenar Veselaj; Nicole Kamber; Myriam Briner; Christoph Friedli; Lara Diem; Kirsten Guse; Andrei Miclea; Roland Wiest; Franca Wagner; Hilary Grabe; Mathias Abegg; Michael P Horn; Sandra Bigi; Andrew Chan; Robert Hoepner; Anke Salmen Journal: CNS Neurosci Ther Date: 2020-10-13 Impact factor: 5.243
Authors: Jana Remlinger; Adrian Madarasz; Kirsten Guse; Robert Hoepner; Maud Bagnoud; Ivo Meli; Moritz Feil; Mathias Abegg; Christopher Linington; Anthony Shock; Babak Boroojerdi; Peter Kiessling; Bryan Smith; Volker Enzmann; Andrew Chan; Anke Salmen Journal: Neurol Neuroimmunol Neuroinflamm Date: 2022-01-13
Authors: Krenar Veselaj; Nicole Kamber; Myriam Briner; Christoph Friedli; Lara Diem; Kirsten Guse; Andrei Miclea; Roland Wiest; Franca Wagner; Hilary Grabe; Mathias Abegg; Michael P Horn; Sandra Bigi; Andrew Chan; Robert Hoepner; Anke Salmen Journal: CNS Neurosci Ther Date: 2020-10-13 Impact factor: 5.243